Based on the 2023 ESMO Pancreatic Cancer Clinical Treatment Guidelines (Conroy et al., 2023), we analyzed the IC50 of five common chemotherapy drugs (gemcitabine, oxaliplatin, fluorouracil, irinotecan, and carboplatin), a NOTCH pathway inhibitor (MK-0752), two mTOR inhibitors (rapamycin and sirolimus), and four tyrosine kinase inhibitors (sorafenib, sunitinib, cabozantinib, and masitinib). Here, MTOR is linked to familial pancreatic carcinoma.